The predominant clinical disease course of multiple sclerosis (MS) which can be treated today by a variety of different disease-modifying treatments (DMT) is characterized by reversible episodes of neurological disability (relapsing remitting form of MS (RRMS)), which frequently evolves into progressive neurological decline (secondary progressive multiple sclerosis (SPMS)) which cannot be treated by DMTs as well.

To stop or not to stop disease modifying therapies in secondary progressive multiple sclerosis, that is the question

D’Amico, Emanuele
Conceptualization
;
2017

Abstract

The predominant clinical disease course of multiple sclerosis (MS) which can be treated today by a variety of different disease-modifying treatments (DMT) is characterized by reversible episodes of neurological disability (relapsing remitting form of MS (RRMS)), which frequently evolves into progressive neurological decline (secondary progressive multiple sclerosis (SPMS)) which cannot be treated by DMTs as well.
DMT; Multiple sclerosis; outcome; secondary progressive multiple sclerosis; therapy; Neuroscience (all); Neurology (clinical); Pharmacology (medical)
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11769/360507
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 5
social impact